Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. All News
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Delayed Nasdaq  -  04:00 2022-10-07 pm EDT
131.26 USD   -3.68%
10/06Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022
BU
10/06RBC Cuts Price Target on Seagen to $185 From $188, Maintains Outperform Rating
MT
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about SEAGEN INC.
10/06Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial R..
BU
10/06RBC Cuts Price Target on Seagen to $185 From $188, Maintains Outperform Rating
MT
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
AQ
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
AQ
09/28Zai Lab Strikes Licensing Deal with Nasdaq-listed Seagen for Cervical Cancer Drug
MT
09/27Zai Lab Signs Exclusive Collaboration, License Agreement With Seagen to Develop, Commer..
MT
09/27Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
BU
09/27Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
CI
09/26Sector Update: Health Care Stocks Fall on Monday
MT
09/26Sector Update: Health Care
MT
09/26Top Midday Gainers
MT
09/26Seagen, Lava Therapeutics Sign License Agreement for Pre-Clinical Asset Targeting Solid..
MT
09/26Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance ..
BU
09/26Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance ..
AQ
09/20US Stocks Fall Tuesday as Fed Policy Meeting Begins
MT
09/20US Stocks Fall Tuesday as Bond Yields Climb; Fed Policy Meeting Begins
MT
09/20Seagen Announces TUKYSA in Combination with Trastuzumab Granted Priority Review by FDA ..
AQ
09/19Seagen Says US FDA Grants Priority Review to Tukysa Plus Trastuzumab for HER2-Positive ..
MT
09/19Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority R..
BU
09/19Seagen Inc. Announces TUKYSA® in Combination with Trastuzumab Granted Priority Review b..
CI
09/19Seagen Gets FDA Priority Review of Tukysa in Colorectal Cancer
DJ
09/14Transcript : Seagen Inc. Presents at Morgan Stanley 20th Annual Global Health..
CI
09/13SVB Securities Adjusts Seagen's Price Target to $160 from $152, Retains Outperform Rati..
MT
09/12Seagen, Merck, Astellas Release Data From Trial of Padcev, Keytruda to Treat Bladder Ca..
MT
09/12Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating Padcev with..
CI
09/12Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (..
CI
09/07Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Soci..
BU
09/07Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Soci..
CI
09/07Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
BU
08/26Sector Update: Health Care Losses Accelerate Just Before Friday Close
MT
08/26Market Chatter: Merck's Talks to Buy Seagen Reportedly Stall Due to Price
MT
08/26Sector Update: Health Care Stocks Sinking with Broader Friday Markets
MT
08/26Sector Update: Health Care
MT
08/26Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal
CI
08/26Merck's Talks to Buy Seagen Reportedly Stall Due to Price
MT
08/25Merck & Co.'s Seagen Deal Talks Said to Stall on Terms
MT
08/17North American Morning Briefing: Investors Seek -2-
DJ
08/16Seagen Upgraded by RBC to Outperform From Sector Perform, Price Target Raised to $188 F..
MT
08/15China blues
MS
08/15Analyst recommendations: Coca-Cola, Dollar General, Comcast, Del..
MS
08/15SVB Securities Adjusts Seagen's Price Target to $152 From $159, Keeps Outperform Rating
MT
08/15Japan Index Rallies on Upbeat Economic Reports; Daiichi Sankyo Soars 14% on Legal Victo..
MT
08/15Nikkei hits over 7-month high on Wall Street optimism, robust earnings
RE
08/14Japanese shares rise on Wall Street optimism, strong earnings
RE
08/14Daiichi Sankyo Shares Gain After It Wins Dispute Over Cancer Drug Technology
DJ
08/12Seagen : Statement on Outcome of Daiichi Sankyo Arbitration - Form 8-K
PU
08/12Seagen Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/12Seagen Loses Arbitration Against Daiichi Sankyo; Sees No Impact on Existing Business
MT
08/12Seagen loses arbitration against Daiichi Sankyo over drug technology
RE
08/12Seagen loses arbitration ruling against Daiichi Sankyo
RE
08/12Seagen Statement on Outcome of Daiichi Sankyo Arbitration
BU
08/01Berenberg Bank Adjusts Seagen's Price Target to $183 From $180, Maintains Buy Rating
MT
07/29Stifel Nicolaus Adjusts Seagen Price Target to $170 From $145, Maintains Hold Rating
MT
07/29Morgan Stanley Raises Seagen's Price Target to $181 From $180, Maintains Overweight Rat..
MT
07/29RBC Boosts Price Target on Seagen to $179 From $136, Maintains Sector Perform Rating
MT
07/28SEAGEN INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
07/28Transcript : Seagen Inc., Q2 2022 Earnings Call, Jul 28, 2022
CI
07/28Seagen Q2 Net Loss Widens, Revenue Rises; Increases 2022 Revenue Guidance
MT
07/28Seattle Genetics : Q2 Earnings Snapshot
AQ
07/28Seagen : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
07/28Earnings Flash (SGEN) SEAGEN Reports Q2 Revenue $497.5M
MT
07/28Earnings Flash (SGEN) SEAGEN Reports Q2 Revenue $497.5M
MT
07/28Seagen Reports Second Quarter 2022 Financial Results
BU
07/28Seagen Inc. Revises Earnings Guidance for the Year 2022
CI
07/28Seagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 3..
CI
07/27Astellas and Seagen Announce Positive Topline Results For PADCEV (enfortumab vedotin-ej..
AQ
07/27It's Fed day - What's in the bag for September?
MS
07/27Needham Adjusts Seagen's Price Target to $188 From $180, Reiterates Buy Rating
MT
07/27HC Wainwright Adjusts Seagen's Price Target to $200 from $170, Keeps Buy Rating
MT
07/27Analyst recommendations: Meta Platforms, McDonald's, Raytheon Te..
MS
07/26Health Care Up on Earnings Optimism -- Health Care Roundup
DJ
07/26Goldman Sachs Raises Price Target for Seagen to $204 From $195, Maintains Buy Rating
MT
07/26Seagen Looks Wells Positioned for Growth Even if Merck's Acquisition Deal Cancels, Oppe..
MT
07/26Sector Update: Health Care Stocks Steady Premarket Tuesday
MT
07/26Seagen, Astellas Report Positive Results for Trials on Padcev with Keytruda as Treatmen..
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on SEAGEN INC.